CHM chimeric therapeutics limited

I agree about the near term re-rating. CEO advised in a recent...

  1. 294 Posts.
    lightbulb Created with Sketch. 92
    I agree about the near term re-rating.

    CEO advised in a recent investor update that the prelim results for the first cohort of CDH17 CART patients will be released very soon (read early January?) - currently waiting on FDA approval.

    this is the lowest dose level in the dose escalation but early signs of safety, efficacy and pharmokinetics should get a lot of market and big pharma interest. this is the first and only CDH17 cart therapy for gastric cancer currently being trialed globally. the FDA would likely assign breakthrough / regen medicine designation if the results are promising....


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $20 5K

Buyers (Bids)

No. Vol. Price($)
27 21893606 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 18543063 26
View Market Depth
Last trade - 11.34am 17/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.